the product in the database has an inactive status
indications:
Prevention of influenza, especially in patients with an increased risk of complications from influenza. The vaccine should be used in accordance with official recommendations.
Composition:
1 dose (0.5 ml) contains surface antigens of the influenza virus corresponding to the following strains: A (H1N1) - 15 μg HA, A (H3N2) - 15 μg HA and B - 15 μg HA (HA - haemagglutinin). The vaccine complies with the WHO recommendations (for the northern hemisphere) and the EU decision for the current season.
Action:
A trivalent inactivated influenza vaccine. The protective effect is achieved within 2-3 weeks. Immunity against homologous strains or strains related to the vaccine strains contained in the vaccine is usually maintained for 6 to 12 months after vaccination.
Contraindications:
Hypersensitivity to active substances, excipients or residues after the production process (eggs, chicken proteins such as ovalbumin, formaldehyde, trimethylcetyl bromide, polysorbate 80, kanamycin and neomycin sulfate). Disease with fever or acute infection (vaccination should be postponed). Do not give intravascularly.
Precautions:
In patients with immune disorders, the immune response may be insufficient.
Pregnancy and lactation:
Limited data on the use of the preparation during pregnancy do not indicate any adverse reactions in the mother or fetus. The use of the vaccine may be considered from the second trimester of pregnancy, however, in pregnant women whose health condition indicates a particular risk of post-influenza complications, the use of the vaccine is recommended regardless of the stage of pregnancy. The preparation can be used during breastfeeding.
Side effects:
Common: headache, sweating, muscle and joint pain, fever, unwellness, chills, fatigue, local reactions (redness, swelling, pain, bruising, induration). In addition, there may be: transient thrombocytopenia, transient generalized enlargement of the lymph nodes, allergic reactions (in rare cases leading to shock), angioneurotic edema, neuralgia, paresthesia, convulsions, neurological disorders (encephalomyelitis, neuritis, Guillan-Barré syndrome) , generalized skin reactions (including pruritus, urticaria, nonspecific rash), vasculitis combined in rare cases with transient changes in the kidneys.
Dosage:
Intramuscularly or deeply subcutaneously. Adults and children from 36 months: 0.5 ml. Children from 6 months up to 35 months: clinical data are limited, doses of 0.25 ml or 0.5 ml are used. Children who have not been vaccinated before the flu should be given a second dose of vaccine after at least 4 weeks.
(C)
